Skip to main content
    B

    BridgeBio Pharma Inc (BBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $76.80
    -0.56 (-0.72%)

    Market Cap: $15.07B

    Last updated: Nov 17, 2026 at 4:23 PM ET

    BridgeBio Pharma Inc (BBIO) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    BridgeBio Pharma (BBIO) has a market cap of $15.07B and an enterprise value of $16.01B. Revenue grew 168.92% over the last 12 months from the 12 months before. It kept -61.08% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 6.26% above the market cap, as debt exceeds cash.

    Market Cap$15.07B
    Enterprise Value$16.01B
    Latest price (Nov 17, 2026)$76.80

    Key Dates

    Last Earnings DateOct 29, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.12% in the quarter ended Sep 30, 2026 and grew 1.97% a year over 2 years.

    Shares Outstanding196.03M
    Shares Change (YoY)+2.18%
    Shares Change (QoQ)+0.12%
    Share Count Growth (2Y CAGR)+1.97%

    Valuation Ratios

    The price to sales ratio is 15.9x. Its year-end P/S ranged from 14.4x to 705.3x from 2019 to 2025.

    P/S Ratio15.9x
    Forward P/S13.7x

    Price Statistics

    The stock is up 15.68% over 52 weeks and trades 9.60% above its 50-day average.

    Beta (1Y)0.95
    52-Week Change+15.68%
    1-Month Change+13.04%
    3-Month Change-8.52%
    6-Month Change+16.36%
    5-Year Change+51.78%
    Total Return (1Y)+15.68%
    Total Return (3Y CAGR)+37.95%
    Total Return (5Y CAGR)+11.35%
    Return vs SPY (1Y)+5.53%
    Max Drawdown (1Y)-29.80%
    Max Drawdown (3Y)-49.08%
    Sharpe Ratio (1Y)0.36
    Correlation with SPY (1Y)0.30
    50-Day Average$70.07
    200-Day Average$72.69
    52-Week Range$62.50 to $93.42
    RSI (14 Days)59.5
    Average Volume (20 Days)2.98M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.09x current liabilities.

    Current Ratio2.09x
    Quick Ratio2.03x
    Interest Coverage-1.60x

    Returns and Efficiency

    Return on invested capital is -33.00% over the last 12 months, against a 5-year average of 205.16%.

    Return on Assets (ROA)-26.72%
    Return on Invested Capital (ROIC)-33.00%
    Return on Capital Employed (ROCE)-28.74%
    ROA (5Y Average)-78.53%
    ROIC (5Y Average)205.16%
    Asset Turnover0.60x
    Inventory Turnover0.95x
    Receivables Turnover3.00x
    Cash Conversion Cycle112 days

    Scores

    BBIO has an Altman Z-Score of 0.16, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score0.16
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $945.54M over the last 12 months.

    Revenue$945.54M
    Revenue Growth (YoY)+168.92%
    Gross Profit$892.00M
    Operating Income-$364.24M
    Pretax Income-$576.47M
    Net Income-$577.58M
    EBITDA-$328.60M
    EBIT-$340.46M
    Reported EPS (TTM)-$2.98

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$1.53B
    Total Debt$2.48B
    Net Debt$944.05M
    Net Debt Per Share$4.82
    Working Capital$1.07B
    Shareholder Equity-$1.66B
    Tangible Book Value-$1.69B
    Total Assets$2.16B
    Total Liabilities$3.82B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $835.00K of capital spending, operating cash flow left -$369.81M of free cash flow.

    Operating Cash Flow-$368.97M
    Capital Expenditures$835.00K
    Free Cash Flow-$369.81M
    FCF Per Share-$1.89
    Depreciation and Amortization$11.87M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -38.52%.

    Gross Margin94.34%
    Operating Margin-38.52%
    Pretax Margin-60.97%
    Net Margin-61.08%
    EBITDA Margin-34.75%
    EBIT Margin-36.01%
    FCF Margin-39.11%
    Gross Margin (5Y Average)91.78%

    Growth

    Revenue grew 86.30% a year over 3 years.

    Revenue Growth (3Y CAGR)+86.30%
    Revenue Growth (5Y CAGR)+127.44%

    Revenue and profit by year

    Dividends and Yields

    BBIO does not pay a dividend. Its free cash flow yield is -2.46%.

    FCF Yield-2.46%
    Buyback Yield1.62%

    Peer Position

    Against 9 similar companies, BBIO has the 3rd highest P/S.

    P/S Ratio15.9x vs 11.1x median
    ROIC-33.00% vs 9.34% median
    Revenue Growth (Trailing 4 Quarters, YoY)+168.92% vs +35.49% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 82.09% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+82.09%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About BBIO

    What is BBIO's market cap?

    BridgeBio Pharma has a market cap of $15.07B. Its enterprise value, which adds debt and subtracts cash, is $16.01B.

    How many shares of BBIO are outstanding?

    BridgeBio Pharma has 196.03M shares outstanding. The count is up 2.18% from a year earlier.

    Does BBIO pay a dividend?

    No. BridgeBio Pharma does not pay a dividend.

    How much debt does BBIO have?

    BridgeBio Pharma has $2.48B of total debt and $1.53B of cash and equivalents, a net debt position of $944.05M.